This HTML5 document contains 145 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n13http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n8https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q42975802
rdf:type
wikibase:Item
schema:description
articolo scientifico 2010年論文 vědecký článek vedecký článok 2010년 논문 জুলাই ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article scientific scientific article published on July 2010 artikel ilmiah scienca artikolo 2010 nî lūn-bûn мақолаи илмӣ 2010年论文 wissenschaftlicher Artikel artigo científico სამეცნიერო სტატია artículu científicu espublizáu en 2010 artikull shkencor 2010年論文 artykuł naukowy επιστημονικό άρθρο 2010年论文 articol științific научна статия tudományos cikk מאמר מדעי vitskapeleg artikkel scientific article published on July 2010 2010年論文 teaduslik artikkel научни чланак artigo científico научни чланак 2010年の論文 2010年论文 videnskabelig artikel 2010年論文 2010年论文 artikulong pang-agham bài báo khoa học wetenschappelijk artikel บทความทางวิทยาศาสตร์ bilimsel makale научная статья vitenskapelig artikkel scientific article published on July 2010 vetenskaplig artikel article scientifique наукова стаття, опублікована в липні 2010 tieteellinen artikkeli article científic 2010年论文 مقالة علمية نشرت في يوليو 2010 artículo científico publicado en 2010 artigo científico 2010年論文 naučni članak 2010年论文
p:P577
wds:Q42975802-D27C9169-8B24-4921-9120-D3F4E18DC204
wdt:P577
2010-07-01T00:00:00Z
p:P2888
wds:Q42975802-6B942E4F-2EAB-4098-91FB-74C63513A8DB
wdt:P2888
n8:s12094-010-0544-2
p:P2860
wds:Q42975802-4595453D-7AFD-4E10-9557-F0CB6138FB51 wds:Q42975802-4A89668C-FA3F-4C53-958C-C9BE0B434728 wds:Q42975802-63DB7092-4DCD-485E-808F-1D7438AEB3FB wds:Q42975802-92912BFA-B018-4796-929E-BAEA9265A6F3 wds:Q42975802-93625E28-F27A-4EA3-A34F-853874A2B526 wds:Q42975802-9377C4FC-8EBC-48F1-948C-365332C6FCA3 wds:Q42975802-93B2363C-0084-419C-B1A6-0029BDBAA2D2 wds:Q42975802-A8E1B652-2111-49B2-A0A0-54FA8AC353F2 wds:Q42975802-ACF20EDD-5460-42BE-9103-45598D95EDFA wds:Q42975802-CE3C81BB-3EE7-4FDC-A514-5B3B4DDD1DEE wds:Q42975802-FAE7F2BF-E24A-4BD4-8DE8-70A6A4230B1C wds:Q42975802-FB8F9D0B-94F6-4EE0-B12A-FB290AAD3967 wds:Q42975802-290DBA2D-09AF-4A3A-A647-EE001963D207 wds:Q42975802-2A3F4016-42BB-4E86-BE33-63614829BBD1 wds:Q42975802-2CB583F9-32AA-44E0-B7E2-B0A55A5214C4 wds:Q42975802-2F59F295-9071-480C-9F1F-C16601E2FD07 wds:Q42975802-31A3232D-F2D2-41BE-B572-C8F3280B16E1
wdt:P2860
wd:Q34293726 wd:Q34488979 wd:Q34586436 wd:Q29618031 wd:Q83195713 wd:Q30887373 wd:Q34575047 wd:Q34615846 wd:Q37117085 wd:Q27860904 wd:Q74660708 wd:Q28282767 wd:Q28282757 wd:Q45264009 wd:Q37261810 wd:Q34468262 wd:Q29618608
p:P2093
wds:Q42975802-CB6775E4-9540-4C5B-882F-475C09D99335 wds:Q42975802-4FDAD510-D1A6-4EF6-9CA3-35A0A97CBC62 wds:Q42975802-B1616B06-7CA3-46BA-A082-3AF835D78948 wds:Q42975802-9E49AD27-E721-4898-BFE0-BD22C9BC0121 wds:Q42975802-0C692D36-D76F-4FFC-877C-3842B4A22ED9 wds:Q42975802-1684528E-47D4-4414-9BFD-648A9A77F98D
wdt:P2093
Vicente Guillem Joaquim Bellmunt Antonio Antón-Torres Pablo Maroto-Rey Leyrer Urruticoechea José M Trigo
rdfs:label
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
skos:prefLabel
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
schema:name
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
p:P50
wds:Q42975802-7C107778-BCA5-4980-8283-FF3302A0C70C wds:Q42975802-1C174CD4-334C-4168-9283-B06CC0C810D6
wdt:P50
wd:Q72326079 wd:Q38546550
p:P1476
wds:Q42975802-8FF7F9ED-B751-48A6-91DA-DB70CE4D33AC
wdt:P1476
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
p:P304
wds:Q42975802-EE20D522-B066-4901-B6D5-9437A5C2DEF2
wdt:P304
503-508
p:P31
wds:Q42975802-BD1367CA-87D1-4ED0-BACB-DB5489EF422A
wdt:P31
wd:Q13442814
p:P921
wds:Q42975802-BC82C942-E4AE-4908-96F3-78DD5676DE57 wds:Q42975802-43861C85-3261-476E-869F-0CFB4FED271E wds:Q42975802-0B88AA7A-18A4-4451-84C6-BCB3A15DBFD6 wds:Q42975802-9311C4BA-1FEB-4C0F-BAEA-014A7A57A621
wdt:P921
wd:Q42824440 wd:Q1427096 wd:Q1164529 wd:Q19000948
p:P698
wds:Q42975802-C2522E93-A0A7-4A85-9029-EFBC748180C9
wdtn:P698
n12:20615828
wdt:P698
20615828
p:P1433
wds:Q42975802-34118763-8E8B-43BB-8462-9C3A4FCABF4B
wdt:P1433
wd:Q15754324
p:P433
wds:Q42975802-BC630FDB-01B2-41B0-AF6E-851D336581ED
p:P478
wds:Q42975802-D7E7AF15-C28E-47A6-BB6A-5228EA51E2E6
wdt:P433
7
wdt:P478
12
p:P356
wds:Q42975802-38733194-00A3-440C-B928-45701C16ED97
wdtn:P356
n13:S12094-010-0544-2
wdt:P356
10.1007/S12094-010-0544-2